OPTIMIZED MULTICOMPONENT DRUG THERAPY WITH COLCHICINE IN THE PREVENTION OF ANGINA RECURRENCE IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION
Article Sidebar
Main Article Content
Abstract
Despite successful percutaneous coronary intervention (PCI), recurrent angina remains a significant clinical problem. This prospective randomized controlled study included 120 patients who had undergone successful PCI. The patients were randomized into two groups of 60 people each. The main group received standard therapy in combination with colchicine at a dose of 0.5 mg/day, while the control group received only standard therapy. The follow-up period was 12 months. The primary endpoint was the frequency of recurrent angina. Secondary endpoints included achievement of target LDL-C levels, changes in inflammatory markers (hs-CRP, IL-6), quality of life (SF-36 and HADS questionnaires), and the frequency of major adverse cardiovascular events (MACE). After 12 months, recurrent angina occurred in 7 (11.7%) patients in the main group compared with 17 (28.3%) patients in the control group (p = 0.006; OR = 0.41; 95% CI 0.19–0.89). The main group showed a statistically more pronounced decrease in hs-CRP (−38.4% vs −12.7%, p < 0.001), a higher rate of achieving the target LDL-C level < 1.4 mmol/L (68.3% vs 41.7%, p < 0.01), and greater improvement in the physical component of health according to the SF-36 scale (+18.4 vs +9.7 points, p < 0.01). The MACE rate was lower in the main group (8.3% vs 18.3%, p = 0.047). Colchicine was well tolerated. The addition of low-dose colchicine to standard therapy significantly reduces recurrent angina, suppresses residual inflammation, and improves long-term prognosis in patients after PCI.
Article Details
References
Агабабян И. Р., Кобилова Н. А., Норматов О. С. У. Зависимость уровня нейтрофилов от состояния пародонта у больных хронической ишемической болезнью сердца //Journal of cardiorespiratory research. – 2023. – Т. 1. – №. 1. – С. 9-13.
Агабабян И. Р., Ярашева З. Х. Эхокардиография в прогнозировании ранней хронической сердечной недостаточности у больных пожилого возраста //Достижения науки и образования. – 2022. – №. 2 (82). – С. 103-108.
Ризаев Э. А., Агабабян И. Р., Арзикулова М. Ш. К. Аутоиммунное воспаление как причинно-следственная связь пародонтита и атеросклероза //Вопросы науки и образования. – 2022. – №. 6 (162). – С. 50-64.
De Luca L., Rosano G. M. C., Spoletini I. Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment //Cardiology Journal. – 2022. – Т. 29. – №. 5. – С. 850-857.
Deftereos S. G. et al. Colchicine in cardiovascular disease: in-depth review //Circulation. – 2022. – Т. 145. – №. 1. – С. 61-78.
Ford T. J., Berry C. Angina: contemporary diagnosis and management //Heart. – 2020. – Т.
Lombardi M. et al. Angina after percutaneous coronary interventions //European Heart Journal. – 2026. – Т. 47. – №. 4. – С. 408-422.
Nelson K., Fuster V., Ridker P. M. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week //Journal of the American College of Cardiology. – 2023. – Т. 82. – №. 7. – С. 648-660.
Niccoli G. et al. Angina after percutaneous coronary intervention: the need for precision medicine //International Journal of Cardiology. – 2017. – Т. 248. – С. 14-19.
Nidorf S. M. et al. Colchicine in patients with chronic coronary disease //New England journal of medicine. – 2020. – Т. 383. – №. 19. – С. 1838-1847.
Samuel M. et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis //European heart journal. – 2025. – Т. 46. – №. 26. – С. 2552-2563.
Tardif J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction //New England journal of medicine. – 2019. – Т. 381. – №. 26. – С. 2497-2505. Research Focus International Scientific Journal, Uzbekistan 275 https://refocus.uz/